Press Releases

Dec 13, 2017

Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma

High and durable response rate in disease without any FDA-approved therapies
Dec 11, 2017

FDA Approves Sanofi's Admelog® (insulin lispro injection)

* First FDA-approved follow-on mealtime insulin
Dec 7, 2017

Sanofi explores combination treatments for multiple myeloma in new late-stage trials

Phase 3 trials will evaluate isatuximab, an anti-CD38 antibody, in combination with other cancer treatments 
Dec 5, 2017

Sanofi and IBM Watson Health real-world analysis showed that individuals not achieving control on basal insulin within 12 months were unlikely to achieve control during the remainder of the two year study
Dec 4, 2017

Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec

First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec

Show per page

Print
Email page
RSS